These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1542283)

  • 21. Antibacterial activity of peritoneal exudate in patients treated with 2 g cefotiam for surgical anti-microbial prophylaxis.
    Miglioli PA; Schoeffel U; Gabroska E; Allerberger F
    Chemotherapy; 1998; 44(3):149-52. PubMed ID: 9612603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new parenteral cephalosporin. SK&F 59962: in vitro and in vivo antibacterial activity and serum levels in experimental animals.
    Actor P; Uri JV; Guarini JR; Zajac I; Phillips L; Sachs CS; DeMarinis RM; Hoover JR; Weisbach JA
    J Antibiot (Tokyo); 1975 Jun; 28(6):471-6. PubMed ID: 238925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative activities of cefotiam and cefazolin against urinary tract infections with Proteus mirabilis in mice.
    Iwahi T; Tsuchiya K
    Antimicrob Agents Chemother; 1980 Aug; 18(2):257-63. PubMed ID: 7004338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model simulation of a single oral dose of cefuroxime axetil and the related in-vitro kill kinetics against four bacterial species.
    Silley P; Monsey D; Harris AM
    J Antimicrob Chemother; 1990 Jan; 25(1):83-90. PubMed ID: 2180892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and in vitro evaluation of cefazolin, a new cephalosporin antibiotic.
    Ries K; Levison ME; Kaye D
    Antimicrob Agents Chemother; 1973 Feb; 3(2):168-74. PubMed ID: 4790584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effects of cefotiam and cefazolin on experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice.
    Nishi T; Tsuchiya K
    Antimicrob Agents Chemother; 1980 Oct; 18(4):549-56. PubMed ID: 7004342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relevance of in vitro antibacterial activities of cefotiam and cefazolin to their therapeutic effects on experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice.
    Nishi T; Nakao M; Tsuchiya K
    J Antibiot (Tokyo); 1981 Feb; 34(2):231-9. PubMed ID: 6271719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of cefazolin, a new cephalosporin antibiotic.
    Reller LB; Karney WW; Beaty HN; Holmes KK; Turck M
    Antimicrob Agents Chemother; 1973 Apr; 3(4):488-97. PubMed ID: 4790605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative plasma bactericidal activity of cephapirin and cefazolin.
    Hottendorf GH; Price KE; Van Harken DR
    Curr Ther Res Clin Exp; 1975 Aug; 18(2):364-70. PubMed ID: 809250
    [No Abstract]   [Full Text] [Related]  

  • 30. Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum.
    Klastersky J; Meunier-Carpentier F; Prevost JM; Staquet M
    J Infect Dis; 1976 Sep; 134(3):271-6. PubMed ID: 977997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of two oral forms of cefuroxime axetil.
    Garraffo R; Drugeon HB; Chiche D
    Fundam Clin Pharmacol; 1997; 11(1):90-5. PubMed ID: 9182082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of cefotiam in the treatment of bacteremia caused by Escherichia coli, Klebsiella species, and Proteus mirabilis: A retrospective study.
    Hashiguchi Y; Oda K; Katanoda T; Nosaka K; Jono H; Saito H
    J Infect Chemother; 2020 Nov; 26(11):1158-1163. PubMed ID: 32828676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Activity of cefazolin against Gram-negative bacteria].
    Dzierzanowska D; Niedźwiecka M; Jakubicz P; Borowski J
    Pol Tyg Lek; 1978 Dec; 33(52):1989-91. PubMed ID: 733630
    [No Abstract]   [Full Text] [Related]  

  • 34. Crossover assessment of serum bactericidal activity and pharmacokinetics of five broad-spectrum cephalosporins in the elderly.
    Deeter RG; Weinstein MP; Swanson KA; Gross JS; Bailey LC
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1007-13. PubMed ID: 2393258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo morphological response of Klebsiella pneumoniae to cefotiam and cefazolin.
    Nakao M; Nishi T; Tsuchiya K
    Antimicrob Agents Chemother; 1981 May; 19(5):901-10. PubMed ID: 6271051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An additional dose of cefazolin for intraoperative prophylaxis.
    Ohge H; Takesue Y; Yokoyama T; Murakami Y; Hiyama E; Yokoyama Y; Kanehiro T; Itaha H; Matsuura Y
    Surg Today; 1999; 29(12):1233-6. PubMed ID: 10639702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams.
    Van der Auwera P
    Antimicrob Agents Chemother; 1992 Mar; 36(3):521-6. PubMed ID: 1622160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of cefazolin and cefuroxime tissue penetration by using a continuous intravenous infusion.
    Connors JE; DiPiro JT; Hayter RG; Hooker KD; Stanfield JA; Young TR
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1128-31. PubMed ID: 2393271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of cefotiam in combination with beta-lactam antibiotics on enterobacterial hospital strains.
    Vanhoof R; Hubrechts JM; Nyssen HJ; Nulens E; Leger J; de Schepper N; Kupperberg E; Couvreur ML
    Pharm Weekbl Sci; 1990 Jun; 12(3):104-6. PubMed ID: 2371139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Potential nephrotoxicity of 2nd generation cephalosporins: cefuroxime versus cefotiam].
    Riegel W; Hörl WH
    Infection; 1993; 21 Suppl 1():S14-6. PubMed ID: 8314287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.